Home > NEWS
Novartis’ Cosentyx beats J&J, Lilly to land first-in-class Chinese psoriasis nod
release time:2019-04-08

Novartis’ psoriasis blockbuster Cosentyx has beaten out rivals from Eli Lilly and Johnson & Johnson as the first interleukin-17A inhibitor approved in China.


China’s National Medical Product Administration has approved Cosentyx to treat moderate-to-severe plaque psoriasis in adult patients, Novartis said Tuesday.


The nod comes months after the Center for Drug Evaluation put Cosentyx among 48 “clinically urgently needed drugs,” for which the agency invites their makers to file applications based on foreign data.


Copyright Copyright (C) 2015-2035 Senova Technology Co. Ltd.
Address: 309# in Building 3 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055  Tel: +86-0755-8670 3119 QQ: 530953397